- Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
-
Kim HR, Jo H, Kim H, Hong J, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ
- KMID: 2538017
- Cancer Res Treat.
- 2023 Jan;55(1):344-349.
- doi: 10.4143/crt.2021.1603
Leptomeningeal metastasis (LM) is a rare but fatal clinical condition with a short survival time. The incidence of LM from epidermal growth factor receptor mutant (EGFRm) non–small cell lung cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
-
Duggirala KB, Lee Y, Lee K
- KMID: 2524143
- Biomol Ther.
- 2022 Jan;30(1):19-27.
- doi: 10.4062/biomolther.2021.047
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase widely expressed in many cancers such as non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad
-
Kang JH, Jang YS, Lee HJ, Lee CY, Shin DY, Oh SH
- KMID: 2470020
- Lab Anim Res.
- 2019 Dec;35(4):221-229.
- doi: 10.1186/s42826-019-0030-0
Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For... -
- CITED
-
- Close
- SHARE
-
- Close
- Methionyl-tRNA Synthetase is a Useful Diagnostic Marker for Lymph Node Metastasis in Non-Small Cell Lung Cancer
-
Lee JM, Kim T, Kim EY, Kim A, Lee DK, Kwon NH, Kim S, Chang YS
- KMID: 2460216
- Yonsei Med J.
- 2019 Nov;60(11):1005-1012.
- doi: 10.3349/ymj.2019.60.11.1005
PURPOSE: Identification of lymph node (LN) metastasis in non-small cell lung cancer (NSCLC) is critical for disease staging and selection of therapeutic modalities. Sometimes it is not possible to obtain... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
-
Cho JH
- KMID: 2400624
- Immune Netw.
- 2017 Dec;17(6):378-391.
- doi: 10.4110/in.2017.17.6.378
Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show... -
- CITED
-
- Close
- SHARE
-
- Close
- Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report
-
Manapov F, Roengvoraphoj O, Li M, Eze C
- KMID: 2386216
- Radiat Oncol J.
- 2017 Jun;35(2):180-184.
- doi: 10.3857/roj.2017.00129
Patients with locally advanced lung cancer and very limited pulmonary function (forced expiratory volume in 1 second [FEV1] ≤ 1 L) have dismal prognosis and undergo palliative treatment or best... -
- CITED
-
- Close
- SHARE
-
- Close
- Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists
-
O'Neill AC, Jagannathan JP, Ramaiya NH
- KMID: 2468118
- Korean J Radiol.
- 2017 Feb;18(1):6-17.
- doi: 10.3348/kjr.2017.18.1.6
Traditionally tumors were classified based on anatomic location but now specific genetic mutations in cancers are leading to treatment of tumors with molecular targeted therapies. This has led to a... -
- CITED
-
- Close
- SHARE
-
- Close
- Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer
-
Jeong YH, Lee CK, Jo K, Hwang SH, Cha J, Lee JW, Yun M, Cho A
- KMID: 2313256
- Nucl Med Mol Imaging.
- 2015 Jun;49(2):108-114.
- doi: 10.1007/s13139-014-0304-2
PURPOSE: The aim of this study was to determine the relationship between [18]-2-fluoro-2-deoxy-D-glucose (FDG) uptake and excision repair cross-complementation group 1 (ERCC-1) expression and to evaluate the prognostic effect of... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer
-
Jung IH, Song SY, Jung J, Cho B, Kwak J, Je HU, Choi W, Jung NH, Kim SS, Choi EK
- KMID: 2138878
- Radiat Oncol J.
- 2015 Jun;33(2):89-97.
- doi: 10.3857/roj.2015.33.2.89
PURPOSE: To evaluate the treatment results in early stage non-small cell lung cancer patients who have undergone fiducial-less CyberKnife radiosurgery (CKRS). MATERIALS AND METHODS: From June 2011 to November 2013, 58... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of Loss of O(6)-Methylguanine DNA Methyltransferase (MGMT) Expression in Non-Small Cell Lung Carcinomas (NSCLCs): with Reference to the Relationship with p53 Overexpression
-
Myong NH
- KMID: 2165964
- Cancer Res Treat.
- 2010 Jun;42(2):95-100.
PURPOSE: Functional inactivation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene has been demonstrated as loss of MGMT protein and suggested that it plays an important role in primary human neoplasia, including... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis
-
Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM, Chang YS
- KMID: 759967
- Korean J Intern Med.
- 2008 Sep;23(3):116-120.
- doi: 10.3904/kjim.2008.23.3.116
BACKGROUND/AIMS: The insulin-like growth factor (IGF) system has been implicated in tumor growth, invasion, and metastasis. However, reports on the IGF-1 receptor (IGF-1R) based on radioimmunoassays are conflicting, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeted Therapy of Lung Cancer
-
Lee KY
- KMID: 2185880
- J Korean Med Assoc.
- 2008 May;51(5):483-491.
- doi: 10.5124/jkma.2008.51.5.483
Atherapeutic plateau has been reached with classical cytotoxic agents in the management of advanced non-small cell lung cancer (NSCLC) patients, even though there has been some modest improvement in overall... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunohistochemical Analysis for the Expression of DR5 TRAIL Receptor and p53 in Non-small Cell Lung Cancer
-
Lee KY, Lee JH, Kim SJ, Yoo KH
- KMID: 1970178
- Tuberc Respir Dis.
- 2008 Apr;64(4):278-284.
- doi: 10.4046/trd.2008.64.4.278
BACKGROUND: TRAIL is a promising anticancer agent which induces selective tumor cell death due to a unique receptor system that includes death receptors and decoy receptors. DR5 TRAIL receptor is... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence and Prognostic Factors of Radiation Pneumonitisin NSCLC Treated with Intensity Modulated Radiation Therapy (IMRT)
-
Kim MS
- KMID: 1381699
- J Korean Soc Ther Radiol Oncol.
- 2008 Mar;26(1):35-44.
- doi: 10.3857/jkstro.2008.26.1.35
PURPOSE: To evaluate the incidence and prognostic factors of treatment-related pneumonitis in non-small-cell lung cancer (NSCLC) patients treated with intensity modulated radiation therapy (IMRT). MATERIALS AND METHODS: One-hundred-five patients... -
- CITED
-
- Close
- SHARE
-
- Close
- High Frequency of Genetic Alterations in Non-small Cell Lung Cancer Detected by Multi-target Fluorescence In Situ Hybridization
-
Kang JU, Koo SH, Kwon KC, Park JW, Shin SY, Kim JM, Jung SS
- KMID: 1785788
- J Korean Med Sci.
- 2007 Sep;22(Suppl):S47-S51.
- doi: 10.3346/jkms.2007.22.S.S47
Detection of genetic alterations could provide a tool as an adjuvant for the diagnosis of non-small cell lung cancer (NSCLC) and to define patients at risk for early relapse. In... -
- CITED
-
- Close
- SHARE
-
- Close
- Paclitaxel and Cisplatin with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Stage IIIB Non-small Cell Lung Cancer
-
Kang KM, Lee GW, Kim HG, Kang JH, Lee WS, Chai GY
- KMID: 2003454
- J Korean Soc Ther Radiol Oncol.
- 2006 Dec;24(4):223-229.
PURPOSE: Combined modality therapy including chemotherapy, surgery and radiotherapy is considered the standard of care for the treatment of stage III non-small cell lung cancer (NSCLC). This study was conducted... -
- CITED
-
- Close
- SHARE
-
- Close
- Promoter -202 A/C Polymorphism of Insulin-like Growth Factor Binding Protein-3 Gene and Non-small Cell Lung Cancer Risk
-
Moon JW, Chang YS, Han CH, Kang SM, Park MS, Byun MK, Chung WY, Park JJ, Yoo KN, Shin JH, Kim YS, Chang J, Kim SK, Kim HJ, Kim SK
- KMID: 2318548
- Tuberc Respir Dis.
- 2005 Apr;58(4):359-366.
BACKGROUND: IGFBP-3 inhibits the mitogenic and anti-apoptotic activity of IGF by blocking the binding of IGF to its receptor. However, under certain circumstances, IGFBP- 3 can enhance the activity of... -
- CITED
-
- Close
- SHARE
-
- Close
- Multimodality Treatement in Patients with Clinical Stage IIIA NSCLC
-
Lee YS, Jang PS, kang HM, Lee JE, Kwon SJ, An JY, Jung SS, Kim JO, Kim SY
- KMID: 2133004
- Tuberc Respir Dis.
- 2004 Dec;57(6):557-566.
- doi: 10.4046/trd.2004.57.6.557
BACKGROUND: To find out effectiveness of multimodality treatments based on induction chemotherapy(CTx) in patients with clinical stage IIIA NSCLC METHODS: From 1997 to 2002, 74 patients with clinical stage IIIA NSCLC... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of PET in Staging Non-Small Cell Lung Cancer
-
Hyun IY
- KMID: 1990845
- Korean J Nucl Med.
- 2004 Dec;38(6):481-485.
Lung cancer has become a leading cause of cancer death in Korea. Accurate staging of non-small cell lung cancer (NSCLC) is essential to the ability to offer a patient the... -
- CITED
-
- Close
- SHARE
-
- Close
- Concurrent Chemoradiation with Weekly Paclitaxel in Locally Advanced Non-small Cell Lung Cancer
-
Bae KW, Song TH, Yang JY, Kim YS, Park JS, Jee YK, Lee KY
- KMID: 2318500
- Tuberc Respir Dis.
- 2004 Oct;57(4):351-357.
BACKGROUND: Paclitaxel is highly beneficial anticancer drug for the treatment of non-small cell lung cancer and has shown remarkable radiosensitizing effect in vitro. We evaluated whether concurrent chemoradiation therapy with... -
- CITED
-
- Close
- SHARE
-
- Close
